ALLO

2.40

2.83% -0.07

Dopo l'orario di chiusura: 2.34 -0.06 -2.50%

Allogene Therapeutics Inc (ALLO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$2.47

Aprire:

$2.56

Volume 24 ore:

4.94M

Relative Volume:

1.00

Capitalizzazione di mercato:

$539.35M

Reddito:

$95,000

Utile/perdita netta:

$-327.27M

Rapporto P/E:

-1.1321

EPS:

-2.12

Flusso di cassa netto:

$-239.25M

1 W Prestazione:

+4.35%

1M Prestazione:

+33.33%

6M Prestazione:

+112.39%

1 anno Prestazione:

+26.98%

Intervallo 1D:

$2.36

$2.73

Intervallo di 1 settimana:

$2.21

$2.73

Portata 52W:

$0.8621

$2.80

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Nome

Allogene Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

(650) 457-2700

Indirizzo

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Dipendente

361

Cinguettio

@AllogeneTx

Prossima data di guadagno

2026-03-12

Ultimi documenti SEC

ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALLO Allogene Therapeutics Inc	2.40	539.35M	95,000	-327.27M	-239.25M	-2.12
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-09	Aggiornamento	Citizens JMP	Mkt Perform → Mkt Outperform
2025-10-10	Downgrade	JP Morgan	Neutral → Underweight
2025-05-14	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
2025-03-14	Aggiornamento	Citizens JMP	Mkt Perform → Mkt Outperform
2024-08-08	Ripresa	Oppenheimer	Outperform
2024-05-31	Iniziato	Piper Sandler	Overweight
2024-01-05	Downgrade	Guggenheim	Buy → Neutral
2024-01-05	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	Iniziato	Citigroup	Buy
2023-06-26	Ripresa	Oppenheimer	Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-01-24	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-12-12	Downgrade	BofA Securities	Buy → Underperform
2022-08-10	Downgrade	Raymond James	Outperform → Mkt Perform
2022-07-15	Aggiornamento	Goldman	Neutral → Buy
2022-06-03	Iniziato	Robert W. Baird	Neutral
2022-02-28	Reiterato	B. Riley Securities	Buy
2021-10-20	Iniziato	Cowen	Outperform
2021-10-08	Downgrade	Goldman	Buy → Neutral
2021-10-08	Downgrade	Stifel	Buy → Hold
2021-09-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-21	Ripresa	Jefferies	Buy
2021-05-20	Aggiornamento	Truist	Hold → Buy
2021-05-14	Iniziato	B. Riley Securities	Buy
2021-01-26	Aggiornamento	Stifel	Hold → Buy
2020-12-10	Ripresa	H.C. Wainwright	Buy
2020-11-24	Iniziato	BofA Securities	Buy
2020-10-23	Iniziato	RBC Capital Mkts	Outperform
2020-06-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-29	Reiterato	H.C. Wainwright	Buy
2020-05-19	Aggiornamento	ROTH Capital	Neutral → Buy
2020-05-15	Aggiornamento	Guggenheim	Neutral → Buy
2020-05-14	Reiterato	H.C. Wainwright	Buy
2020-05-14	Downgrade	SunTrust	Buy → Hold
2020-04-13	Iniziato	SunTrust	Buy
2020-03-13	Iniziato	H.C. Wainwright	Buy
2020-03-05	Iniziato	Stifel	Hold
2020-02-24	Iniziato	Berenberg	Hold
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-11-04	Iniziato	Canaccord Genuity	Buy
2019-08-09	Iniziato	BTIG Research	Buy
2019-06-05	Iniziato	ROTH Capital	Neutral
2019-05-31	Iniziato	Guggenheim	Neutral
2019-05-23	Iniziato	Stifel	Hold
2019-03-29	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

Mar 14, 2026

Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com

Mar 14, 2026

Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs - MSN

Mar 14, 2026

Mar 13, 2026

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com

Mar 13, 2026

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - AOL.com

Mar 13, 2026

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView

Mar 13, 2026

Take the Zacks approach to beat the markets: Starbucks, Amgen, Allogene in focus - MSN

Mar 13, 2026

El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Benzinga

Mar 13, 2026

Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 13, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 13, 2026

Allogene Therapeutics (ALLO) Projects Key Milestones for 2026 - GuruFocus

Mar 13, 2026

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Sahm

Mar 13, 2026

Mar 12, 2026

Allogene Therapeutics 2025 Annual Report: Advancing Allogeneic CAR T Cell Therapies for Cancer and Autoimmune Diseases - Minichart

Mar 12, 2026